Characteristics of B-CLL patients and CpG ODN-induced apoptosis
| CLL patient . | Sex . | Age, y . | Rai stage . | B-CLL cells, percentage* . | Cytogenetic or mutational status† . | B-CLL cell counts after treatment, percentage‡ . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| No CpG . | CpG 2216 . | CpG PB4 . | CpG 2006 . | CpG 685 . | ||||||
| 1 | Female | 39 | IV | 92.3 | del (13q), p53 mutations | 78.5 | 68.2 | 76.9 | 10.2 | 7.7 |
| 2 | Male | 62 | IV | 79.8 | del (11q), del (13q), complex karyotype | 79.8 | 62.9 | 63.3 | 31.3 | 15.2 |
| 3 | Female | 43 | 0 | 76.9 | NA | 64.4 | 57.8 | 59.4 | 17.1 | 12.9 |
| 4 | Male | 58 | IV | 85.4 | del (13q), complex karyotype | 76.4 | 72.8 | 82.2 | 23.2 | 17.5 |
| 5 | Male | 49 | IV | 71.4 | del (11q), del (13q), del (Y) | 82.4 | 84.3 | 72.2 | 15.2 | 13.3 |
| 6 | Male | 48 | IV | 97.8 | del (11q) | 76.4 | 72.9 | 91.3 | 78.8 | 78.8 |
| 7 | Female | 50 | 0 | 43.0 | del (13q) | 75.9 | 67.8 | 79.5 | 40.0 | 9.3 |
| 8 | Female | 56 | 0 | 46.7 | NA | 85.2 | 67.5 | 83.7 | 16.5 | 9.9 |
| 9 | Female | 50 | 0 | 77.9 | NA | 90.2 | 68.4 | 79.6 | 46.0 | 12.8 |
| 10 | Male | 76 | IV | 63.0 | del (13q), p53 mutations | 89.0 | 78.5 | 87.0 | 68.9 | 66.0 |
| 11 | Female | 59 | IV | 88.2 | del (11q), del (Y) | 72.4 | 62.5 | 64.0 | 39.0 | 7.7 |
| 12 | Female | 75 | III | 92.9 | del (13q) | 79.2 | 70.4 | 76.5 | 20.0 | 8.6 |
| 13 | Male | 62 | II | 80.2 | del (13q), del (17p), p53 mutations | 82.0 | 53.6 | 80.6 | 11.6 | 10.5 |
| 14 | Male | 60 | I | 73.8 | del (13q) | 86.3 | 92.1 | 76.0 | 11.3 | 10.0 |
| 15 | Male | 78 | I | 68.0 | No abnormalities | 84.6 | 90.3 | 91.8 | 64.2 | 63.0 |
| 16 | Male | 51 | I | 51.7 | No abnormalities | 72.8 | 86.4 | 86.5 | 19.5 | 16.7 |
| 17 | Male | 57 | IV | 92.3 | del (11q) | 67.9 | 52.7 | 58.2 | 63.8 | 51.8 |
| 18 | Male | 53 | III | 70.3 | del (13q) | 74.9 | 73.3 | 73.4 | 13.2 | 10.7 |
| 19 | Male | 70 | IV | 91.7 | del (11q), del (13q) | 77.7 | 74.4 | 81.0 | 32.7 | 26.7 |
| 20 | Male | 76 | IV | 80.0 | del (13q) | 80.2 | 79.5 | 81.9 | 50.7 | 42.1 |
| 21 | Female | 82 | II | 64.9 | NA | 80.4 | 78.6 | 86.3 | 25.2 | 21.9 |
| 22 | Male | 55 | III | 88.1 | del (17p) | 77.6 | 75.4 | 73.8 | 15.6 | 16.3 |
| 23 | Male | 68 | 0 | 57.1 | del (13q) | 70.7 | 70.4 | 67.3 | 17.7 | 10.4 |
| CLL patient . | Sex . | Age, y . | Rai stage . | B-CLL cells, percentage* . | Cytogenetic or mutational status† . | B-CLL cell counts after treatment, percentage‡ . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| No CpG . | CpG 2216 . | CpG PB4 . | CpG 2006 . | CpG 685 . | ||||||
| 1 | Female | 39 | IV | 92.3 | del (13q), p53 mutations | 78.5 | 68.2 | 76.9 | 10.2 | 7.7 |
| 2 | Male | 62 | IV | 79.8 | del (11q), del (13q), complex karyotype | 79.8 | 62.9 | 63.3 | 31.3 | 15.2 |
| 3 | Female | 43 | 0 | 76.9 | NA | 64.4 | 57.8 | 59.4 | 17.1 | 12.9 |
| 4 | Male | 58 | IV | 85.4 | del (13q), complex karyotype | 76.4 | 72.8 | 82.2 | 23.2 | 17.5 |
| 5 | Male | 49 | IV | 71.4 | del (11q), del (13q), del (Y) | 82.4 | 84.3 | 72.2 | 15.2 | 13.3 |
| 6 | Male | 48 | IV | 97.8 | del (11q) | 76.4 | 72.9 | 91.3 | 78.8 | 78.8 |
| 7 | Female | 50 | 0 | 43.0 | del (13q) | 75.9 | 67.8 | 79.5 | 40.0 | 9.3 |
| 8 | Female | 56 | 0 | 46.7 | NA | 85.2 | 67.5 | 83.7 | 16.5 | 9.9 |
| 9 | Female | 50 | 0 | 77.9 | NA | 90.2 | 68.4 | 79.6 | 46.0 | 12.8 |
| 10 | Male | 76 | IV | 63.0 | del (13q), p53 mutations | 89.0 | 78.5 | 87.0 | 68.9 | 66.0 |
| 11 | Female | 59 | IV | 88.2 | del (11q), del (Y) | 72.4 | 62.5 | 64.0 | 39.0 | 7.7 |
| 12 | Female | 75 | III | 92.9 | del (13q) | 79.2 | 70.4 | 76.5 | 20.0 | 8.6 |
| 13 | Male | 62 | II | 80.2 | del (13q), del (17p), p53 mutations | 82.0 | 53.6 | 80.6 | 11.6 | 10.5 |
| 14 | Male | 60 | I | 73.8 | del (13q) | 86.3 | 92.1 | 76.0 | 11.3 | 10.0 |
| 15 | Male | 78 | I | 68.0 | No abnormalities | 84.6 | 90.3 | 91.8 | 64.2 | 63.0 |
| 16 | Male | 51 | I | 51.7 | No abnormalities | 72.8 | 86.4 | 86.5 | 19.5 | 16.7 |
| 17 | Male | 57 | IV | 92.3 | del (11q) | 67.9 | 52.7 | 58.2 | 63.8 | 51.8 |
| 18 | Male | 53 | III | 70.3 | del (13q) | 74.9 | 73.3 | 73.4 | 13.2 | 10.7 |
| 19 | Male | 70 | IV | 91.7 | del (11q), del (13q) | 77.7 | 74.4 | 81.0 | 32.7 | 26.7 |
| 20 | Male | 76 | IV | 80.0 | del (13q) | 80.2 | 79.5 | 81.9 | 50.7 | 42.1 |
| 21 | Female | 82 | II | 64.9 | NA | 80.4 | 78.6 | 86.3 | 25.2 | 21.9 |
| 22 | Male | 55 | III | 88.1 | del (17p) | 77.6 | 75.4 | 73.8 | 15.6 | 16.3 |
| 23 | Male | 68 | 0 | 57.1 | del (13q) | 70.7 | 70.4 | 67.3 | 17.7 | 10.4 |
B-CLL indicates B-cell chronic lymphocytic leukemia; ODN, oligodeoxynucleotide; and NA, patients have asymptomatic, indolent course of CLL; cytogenetic data not available.
Data are percentage of CD19+CD5+CD23+ B-CLL cells presented in peripheral blood samples collected from individual CLL patients. Immunophenotyping of the CD19+CD5+CD23+ expressed on B-CLL cells was determined by flow cytometric analysis.
Cytogenetic abnormalities and p53 mutations/deletions of individual CLL patients. Interphase fluorescence in situ hybridization analysis was performed using Vysis LSI ATM (11q22.3), LSI D13S319 (13q14.3), and LSI p53 (17p13.1) probes.
Purified B-CLL cells from individual patients were cultured in media with or without the indicated CpG-A or CpG-B ODN for 5 days. B-CLL cells of all treatment groups were counted, stained with TMRE, and determined by flow cytometry. Data are percentage of viable B-CLL cells remaining at day 5 cultures.